Investing
US FDA panel votes against Merck’s chronic cough drug
© Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo
(Reuters) – The U.S. health regulator’s advisers on Friday did not recommend Merck’s drug for the treatment of chronic cough.
The FDA panel voted 12 to 1 that the data presented does not demonstrate substantial evidence of effectiveness of the oral tablet, gefapixant, for the treatment of refractory or unexplained chronic cough.
Read the full article here
What to Do If TikTok is Banned — How to Protect Your Brand
10 Roles That Are Surprisingly Well-Suited for Outsourcing
How AI Can Make Us Better Leaders
How Pets Can Promote Better Health and Well-Being in the Workplace
Biden cancels more student loans with one week left to his term
10 Critical Questions to Ask Your Financial Advisor Now
10 Ways to Make Money As a Graphic Designer
Could Easier Cancellations Build Customer Loyalty?
If you are 60 years old, new 401(k) rules could save you money
Airbus keeps top spot with 766 jet deliveries in 2024 By Reuters
Debt ceiling debate and its effect on the U.S. dollar
Debt ceiling default: Still no deal between parties
Stovall: If the U.S. defaults on its debt, all S&P 500 sectors will likely fall
What China's weaker-than-expected economy could mean for U.S. markets
A ‘Big Short’ investor sees financial disaster brewing in housing markets — again
-
Make Money6 days ago10 Critical Questions to Ask Your Financial Advisor Now
-
Make Money5 days ago10 Ways to Make Money As a Graphic Designer
-
Investing5 days agoCould Easier Cancellations Build Customer Loyalty?
-
Personal Finance4 days agoIf you are 60 years old, new 401(k) rules could save you money
-
Investing6 days agoAirbus keeps top spot with 766 jet deliveries in 2024 By Reuters
-
Investing3 days agoBank regulator gives BlackRock new deadline on bank stakes, Bloomberg reports By Reuters
-
Side Hustles5 days agoTrump’s 2025 Inaugural Committee Raises Record $170 Million
-
Passive Income6 days agoHow to Build a Solid Go-to-Market Strategy for 2025